In vivo growth of WHIM20, PMS2 mutant, ER+/HER2− PDX tumors xenografted into mouse mammary fat pads demonstrated a similar pattern of tumor regression in response to combination of lapatinib and fulvestrant but not in response to either treatment alone (Fig. 5C). The gene discussed is PMS2; the disease is neoplasm.